HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

AbbVie

Status: Completed

Conditions: Uveitis

Study type: Observational

Funder types: Industry

Identifiers

NCT02916017

P15-665

Details and patient eligibility

About

This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.

Enrollment: 259 patients

Sex: All

Ages: Under 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Exclusion criteria

• Participants previously treated with adalimumab

Trial design

259 participants in 1 patient group

Participants receiving adalimumab

Description:

Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis